NYSE · Healthcare · Medical Devices · Ireland
Medtronic Plc is a large cap company (market value between $10 billion and $200 billion) in the Medical Devices industry.
Medtronic plc is a healthcare technology company headquartered in Ireland that develops, manufactures, and distributes device-based medical therapies. The company operates through three segments: Cardiovascular Portfolio, offering products for heart rhythm and vascular disorders; Neuroscience Portfolio, providing neurological and spinal solutions; and Medical Surgical Portfolio. It supplies products and services to medical professionals and patients worldwide.
From its FY2026 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Medtronic Plc stock.
Slightly overvalued: intrinsic value $78.75 per share, market price $92.77, margin of safety -17.8% (as of 2026-10-19).
Discounting its cash flows at 8.0% (average of 3 methods) values the shares at $78.75; the price of $92.77 is 18% above that value, and 79% of that value comes from beyond year five.
Leak Score: 48/100 on 12 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 142 Medical Devices stocks
21 more in this industry show a wider margin of safety.
MDT is slightly overvalued (as of the 2026-10-19 close). Discounting its cash flows at 8.0% (average of 3 methods) values the shares at $78.75; the price of $92.77 is 18% above that value, and 79% of that value comes from beyond year five.
$78.75 per share (as of the 2026-10-19 close), against a market price of $92.77. That is a margin of safety of -17.8%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
The price asks for roughly the growth the company has already delivered. No miracle needed, no discount either. Yearly sales growth the price needs: 8.4%. Yearly sales growth it has sustained: 3.6%.
48 out of 100, which we rate "On Watch", on 12 of 12 value investing signals.